Technology thesis · Biotechnology & Health
high conviction established growthCRISPR gene editing
CRISPR has crossed from lab tool to approved cure: ex vivo therapies like Casgevy are commercial, and the next decade turns on in vivo editing of non-liver tissue, where delivery is the hard part.
Position maintained continuously · last reviewed Jun 24, 2026
The thesis
Core thesis
CRISPR has crossed from research tool to approved therapy. Casgevy (CRISPR Therapeutics, 2023) proved clinical viability for sickle cell. The frontier is now in vivo delivery — editing genes inside the body. Intellia leads with liver-targeted NTLA-2001 (hATTR), but a patient death from liver toxicity and subsequent FDA hold revealed the delivery challenge. ~250 CRISPR clinical trials active globally. The winner of the next decade is whoever solves delivery for non-liver tissues.
State of the art (2026)
CRISPR is now a commercial modality, not a promise. Vertex and CRISPR Therapeutics' Casgevy reached roughly $116M of full-year 2025 revenue, with about 64 patients infused over full-year 2025 and is reimbursed for ~90% of eligible US patients, proving the ex vivo sickle-cell cure can scale despite busulfan conditioning friction. The live frontier is in vivo editing. Intellia's nex-z (NTLA-2001) cleared its FDA holds on the MAGNITUDE Phase 3 trials in early 2026, with a BLA realistically around 2028, while Lilly – which bought Verve in June 2025 – is advancing the VERVE-102 base editor that cut LDL-C up to 62% in Phase 1. The FDA's February 2026 Plausible Mechanism Framework opens a master-protocol route for ultra-rare editing programmes.
Beyond Cas9: precision editing without breaks
Base editing (Beam Therapeutics) and prime editing (Prime Medicine) modify DNA without double-strand breaks — dramatically reducing off-target risk. Epigenetic editing can silence genes without changing DNA sequence at all. These 'CRISPR 2.0' approaches are earlier-stage but potentially safer for widespread use.
Everything below is live inside CanaryIQ
The full analysis behind the verdict — the structure is real; the content unlocks when you log in.
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what — and who depends on whom
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers — each with a remove-by condition
Decision frameworks
The same call, framed for your desk
Thesis changelog
When our view changed, and why
Change our mind
3 disconfirming conditions
Comparable wave
The historical analogue on the S-curve
Common mistakes
What the market gets wrong right now
The rest is inside
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and the changelog of every time our call on CRISPR gene editing has changed — all live inside CanaryIQ.